Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Body surface area predicts plasma oxaliplatin and pharmacokinetic advantage in hyperthermic intraoperative intraperitoneal chemotherapy.

Leinwand JC, Bates GE, Allendorf JD, Chabot JA, Lewin SN, Taub RN.

Ann Surg Oncol. 2013 Apr;20(4):1101-4. doi: 10.1245/s10434-012-2790-8. Epub 2013 Mar 2.

2.

Effect of perfusion temperature on glucose and electrolyte transport during hyperthermic intraperitoneal chemoperfusion (HIPEC) with oxaliplatin.

Ceelen W, De Somer F, Van Nieuwenhove Y, Vande Putte D, Pattyn P.

Eur J Surg Oncol. 2013 Jul;39(7):754-9. doi: 10.1016/j.ejso.2012.07.120. Epub 2012 Aug 9.

PMID:
22878060
3.

Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years.

Vaira M, Cioppa T, D'Amico S, de Marco G, D'Alessandro M, Fiorentini G, De Simone M.

In Vivo. 2010 Jan-Feb;24(1):79-84.

PMID:
20133981
4.

Pharmacokinetics of oxaliplatin during open versus laparoscopically assisted heated intraoperative intraperitoneal chemotherapy (HIPEC): an experimental study.

Gesson-Paute A, Ferron G, Thomas F, de Lara EC, Chatelut E, Querleu D.

Ann Surg Oncol. 2008 Jan;15(1):339-44. Epub 2007 Oct 18.

PMID:
17943387
5.

Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis.

Marcotte E, Dubé P, Drolet P, Mitchell A, Frenette S, Leblanc G, Leclerc YE, Sideris L.

World J Surg Oncol. 2014 Nov 7;12:332. doi: 10.1186/1477-7819-12-332.

6.
7.

The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery.

Prada-Villaverde A, Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, Baratti D, Baumgartner JM, Berri R, Bretcha-Boix P, Deraco M, Flores-Ayala G, Glehen O, Gomez-Portilla A, González-Moreno S, Goodman M, Halkia E, Kusamura S, Moller M, Passot G, Pocard M, Salti G, Sardi A, Senthil M, Spiliotis J, Torres-Melero J, Turaga K, Trout R.

J Surg Oncol. 2014 Dec;110(7):779-85. doi: 10.1002/jso.23728. Epub 2014 Aug 2.

PMID:
25088304
8.

The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study.

Hompes D, D'Hoore A, Van Cutsem E, Fieuws S, Ceelen W, Peeters M, Van der Speeten K, Bertrand C, Legendre H, Kerger J.

Ann Surg Oncol. 2012 Jul;19(7):2186-94. doi: 10.1245/s10434-012-2264-z. Epub 2012 Mar 7.

PMID:
22395983
9.

Pharmacokinetics of intraperitoneal oxaliplatin: experimental studies.

Pestieau SR, Belliveau JF, Griffin H, Stuart OA, Sugarbaker PH.

J Surg Oncol. 2001 Feb;76(2):106-14.

PMID:
11223836
10.

Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study.

de Bree E, Rosing H, Filis D, Romanos J, Melisssourgaki M, Daskalakis M, Pilatou M, Sanidas E, Taflampas P, Kalbakis K, Beijnen JH, Tsiftsis DD.

Ann Surg Oncol. 2008 Apr;15(4):1183-92. doi: 10.1245/s10434-007-9792-y. Epub 2008 Feb 1.

PMID:
18239973
11.

Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).

Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M.

Ann Surg Oncol. 2009 Feb;16(2):463-72. doi: 10.1245/s10434-008-0219-1. Epub 2008 Dec 12.

PMID:
19082859
12.

Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results.

Golse N, Bakrin N, Passot G, Mohamed F, Vaudoyer D, Gilly FN, Glehen O, Cotte E.

J Surg Oncol. 2012 Aug 1;106(2):197-203. doi: 10.1002/jso.23062. Epub 2012 Feb 13.

PMID:
22331814
13.

Hemophagocytic syndrome: an unusual and underestimated complication of cytoreduction surgery with heated intraperitoneal oxaliplatin.

Schwarz L, Bridoux V, Veber B, Oksenhendler E, Royon V, Michot F, Tuech JJ.

Ann Surg Oncol. 2013 Nov;20(12):3919-26. doi: 10.1245/s10434-013-3099-y. Epub 2013 Jul 10.

PMID:
23838919
14.

Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience.

Wong J, Koch AL, Deneve JL, Fulp W, Tanvetyanon T, Dessureault S.

Ann Surg Oncol. 2014 May;21(5):1480-6. doi: 10.1245/s10434-013-3341-7. Epub 2013 Oct 25.

PMID:
24158467
15.
16.

Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution.

Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El OA, Pignon JP, Drouard-Troalen L, Ouellet JF, Ducreux M.

Ann Oncol. 2002 Feb;13(2):267-72.

PMID:
11886004
17.

[Treatment of peritoneal carcinomatosis with surgery and hyperthermic peroperative intraperitoneal chemotherapy (HIPEC): new aspects and validated indications].

Eveno C, Dagois S, Guillot E, Gornet JM, Pocard M.

Bull Cancer. 2008 Jan;95(1):141-5. doi: 10.1684/bdc.2008.0553. Review. French.

18.

Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Baratti D, Kusamura S, Martinetti A, Seregni E, Laterza B, Oliva DG, Deraco M.

Ann Surg Oncol. 2007 Aug;14(8):2300-8. Epub 2007 May 18.

PMID:
17510772
19.

Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases.

Yang XJ, Li Y, al-shammaa Hassan AH, Yang GL, Liu SY, Lu YL, Zhang JW, Yonemura Y.

Ann Surg Oncol. 2009 Feb;16(2):345-51. doi: 10.1245/s10434-008-0226-2. Epub 2008 Nov 19.

PMID:
19018599
20.

Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin C.

Sugarbaker PH, Stuart OA, Carmignani CP.

Cancer Chemother Pharmacol. 2006 May;57(5):703-8. Epub 2005 Aug 11.

PMID:
16096789

Supplemental Content

Support Center